Enspryng
- Product NDC
- 50242-005
- 11-digit product format
- 502420005
- Labeler code
- 50242
- Product ID
- 50242-005_63a8ff00-ffa2-4f6f-84fb-338e7aa7c160
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Satralizumab
- Dosage form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Labeler
- Genentech, Inc.
- Application
- BLA761149
- Marketing category
- BLA
- Marketing start
- 2026-10-15
- Substance
- SATRALIZUMAB
- Active strength
- 180 mg/1.5mL
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Enspryng
- Listing expiration
- 2027-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| SATRALIZUMAB | 180 mg/1.5mL |
DailyMed Product Concepts#
Purple Book Biologic Products#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 761149 | Enspryng | satralizumab-mwge | 351(a) | Rx | 2026-10-01 |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|
| 50242-005-01 | 50242000501 | 1 SYRINGE, PLASTIC in 1 CARTON (50242-005-01) / 1.5 mL in 1 SYRINGE, PLASTIC | 2026-10-15 | No | No | Current |
| 50242-005-86 | 50242000586 | 1 SYRINGE, PLASTIC in 1 CARTON (50242-005-86) / 1.5 mL in 1 SYRINGE, PLASTIC | 2026-10-15 | Yes | No | Current |